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INTRODUCTION 
Abiraterone is an active pharmaceutical ingredient (API) that 
is used for the treatment of hormone-resistant prostate cancers 
[1]. Due to the action of the human xenobiotic metabolism, 
Abiraterone undergoes various chemical modifications to form 
the phase II metabolite, Abiraterone-O- β-D- glucuronide [2]. 
This process occurs due to the highly soluble nature of 
glucuronides and their ability to act as effective agents in drug 
excretion. As a consequence, Abiraterone-O- β-D- glucuronide 
normally presents itself in urine and is thus essential for 
toxicological testing and an analysis of the pharmacological 
activity of Abiraterone [2]. However, in order to confirm the 
identity of Abiraterone-O- β-D- glucuronide and quantify the 
amount metabolised within the body via liquid 
chromatography-mass spectrophotometry (LC-MS) based 
assays and nuclear magnetic resonance (NMR) requires a 
reference standard that completely resembles the native form 
of the metabolite.  
METHODS 
The first step entails the protection of the hydroxyl moieties on 
a methyl glucuronate molecule via pivaloyl chloride. This is 
followed by the selective deprotection of the C1 hydroxyl 
group and the addition of an imidate moiety to form and 
activate a glucuronyl donor. The next stage involves the 
coupling of this glucuronyl donor with Abiraterone in the 
presence of boron trifluoride etherate to synthesize the final 
intermediate. Abiraterone-O- β-D- glucuronide is produced via 
deprotection of the remaining hydroxyl groups in 
tetrabutylammonium hydroxide. The final product is isolated 
through column chromatography. 
RESULTS 
A total of 137mg of Abiraterone-O- β-D- glucuronide was 
produced which corresponds to an overall yield of 26%. LC-
MS analysis as shown in Figure 1 reveals a final purity of 
>98%. NMR results were consistent with the structure of the 
final compound.  
 
Figure 1. Liquid chromatography-mass spectrophotometry 
(LCMS) analysis of the Abiraterone-O- β-D- glucuronide. The 
graphs y-axis denotes relative abundance and the x-axis 
denotes retention time. The graph shows a single distinct peak 
representing the final compound with no intruding impurity 
peaks. Overall, the final compounds purity is >98%.  
DISCUSSION AND CONCLUSIONS 
This research shows that pure synthetic Abiraterone-O- β-D- 
glucuronide can be successfully synthesized and used as a 
reference standard for clinical trials.  
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